Drug intelligence / Profile preview

Dyno-hc9

Development stage: Preclinical
Lead developer: Dyno Therapeutics
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Dyno-hc9 (also known as Dyno bCap 1) is an AI-designed adeno-associated virus (AAV) capsid developed by Dyno Therapeutics. It is optimized for efficient gene delivery to the brain and central nervous system (CNS), offering improved transduction efficiency compared to standard AAV capsids such as AAV9. The technology enables widespread CNS delivery via intravenous injection, with significant liver detargeting and a mechanism for crossing the blood-brain barrier that is conserved between non-human primates and humans. This makes it a promising vector for next-generation gene therapies targeting neurological diseases[1].

Brand names: Dyno-hc9Dyno-hc-9Dyno-hc 9Dyno bCap 1

Beyond the preview

Go deeper on Dyno-hc9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dyno-hc9.

Explore the full profile